In this abstract we review the pancreatic cancer epigenetic mark up and the impact of related therapies on preclinical and clinical outcome. We explore the potentials of combination therapies with targeted drugs in a protocol called multitargeted epigenetic therapies (MTET) with a specific focus on intratumoral hypoxia and angiogenesis. We share our invitro data as well as a review of case studies of advanced pancreatic cancer treated with such protocol and we conclude that such combination

more »

... apy appears to be superior in the cases studied to the standard of care alone. Further clinical trials are needed to support such hypothesis and validate the companion diagnostics associated with the therapy.